BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/12/2024 7:44:53 AM | Browse: 319 | Download: 685
Publication Name World Journal of Meta-Analysis
Manuscript ID 95755
Country Colombia
ISSN 2308-3840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https: //creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Nuclear Science & Technology
Manuscript Type Minireviews
Article Title Fibroblast activation protein inhibitors positron emission tomography/computed tomography: Review of the literature
Manuscript Source Invited Manuscript
All Author List Nathalie Hernandez-Hidalgo, Gerardo Cortes, Klissman Ortega-Anaya and Humberto Varela
ORCID
Author(s) ORCID Number
Nathalie Hernandez-Hidalgo http://orcid.org/0000-0002-7471-9566
Gerardo Cortes http://orcid.org/0000-0003-0315-1464
Klissman Ortega-Anaya http://orcid.org/0009-0008-1788-7548
Humberto Varela http://orcid.org/0000-0002-5665-5087
Funding Agency and Grant Number
Corresponding Author Nathalie Hernandez-Hidalgo, MD, Academic Research, Doctor, Doctor, Department of Nuclear Medicine, Instituto Nacional de Cancerologia, Cl.1#9-85, Bogota 111321, Colombia. nathaliehh2809@gmail.com
Key Words Fibroblast activation protein inhibitors; Fibroblast activation protein; Positron emission tomography/computed tomography; Cancer
Core Tip Fibroblast activation protein inhibitors (FAPI) has been a protagonist in the most recent research in the field of nuclear medicine and oncology, demonstrating surprising diagnostic versatility with a dizzying rise, due to its successful labeling with radioisotopes (Ga68 and F18). In the comparative clinical studies that have been carried out to date, it appears that FAPI is superior to fluorodeoxyglucose in oncological diagnostic performance, according to certain advantages it has, mainly related to a better lesion-to-background ratio, lower radiation dose, non-dependence on glucose level or preparatory diet, low brain uptake and its promising use as a theragnostic. FAPI positron emission tomography/computed tomography constitutes a great challenge to address for nuclear medicine and current oncology, which is approaching our present by leaps and bounds, possibly marking a new route in the approach and treatment of oncological diseases.
Publish Date 2024-12-12 07:44
Citation

Hernandez-Hidalgo N, Cortes G, Ortega-Anaya K, Varela H. Fibroblast activation protein inhibitors positron emission tomography/computed tomography: Review of the literature. World J Meta-Anal 2024; 12(4): 95755

URL https://www.wjgnet.com/2308-3840/full/v12/i4/95755.htm
DOI https://dx.doi.org/10.13105/wjma.v12.i4.95755
Full Article (PDF) WJMA-12-95755-with-cover.pdf